🔔 In this episode of #OncLiveOnAir, Drs Sandip Patel, M.D. and Brendon Stiles, MD, of UC San Diego Health and Montefiore Health System, discuss the significance of the FDA approval of perioperative durvalumab for patients with resectable non–small cell #LungCancer. 🎙 Listen here: https://lnkd.in/ei4xTswv
About us
OncLive is the official website for the Intellisphere, LLC Oncology Specialty Group, which publishes OncologyLive, Urologists in Cancer Care, Oncology Nursing News, and Oncology Fellows. The mission of OncLive is to arm oncology professionals with the resources and information they need to provide the best patient care. We cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. OncLive allows the Oncology Specialty Group to add features and tools not possible with print, such as social media feeds, breaking news, and live coverage from major oncology meetings.
- Website
-
http://onclive.com
External link for OncLive
- Industry
- Book and Periodical Publishing
- Company size
- 51-200 employees
- Headquarters
- Cranbury, NJ
- Type
- Privately Held
Locations
-
Primary
2 Clarke Dr
Cranbury, NJ 08512, US
Employees at OncLive
-
Chandler Park, M.D., F.A.C.P.
Award Winning Oncologist| 3x NEJM Published Author| ASCO Faculty|Advisory Dean/Clinical Professor UofL Medical School|Kentucky Leader ASCO ASH NCCN…
-
Morgan Burum
Director of Sales
-
Gabrielle Gelchion
National Account Manager, Onclive Events™
-
Jack Nirenberg
National Account Associate at OncLive | Working With Commercial Oncology Partners on NPP and P2P Marketing Solutions
Updates
-
Tune in to watch Joyce A. O'Shaughnessy, MD, Melinda L. Telli, MD, Aditya Bardia, MD, MPH, Ian Krop, MD, PhD, and Kandace McGuire, MD discuss persisting unmet needs and the future directions of HER2 Breast Cancer treatment. https://lnkd.in/eF5fZini
-
Health Canada | Santé Canada approved Illuccix for selecting mCRPC patients eligible for lutetium Lu 177 vipivotide tetraxetan treatment. #oncology #CRPC https://lnkd.in/eTgeRwMq
-
Too busy this week to stay on top of the top oncology news? Don't worry - you have the 🌟 #OncFive 🌟: https://lnkd.in/eJYVxrPf 1️⃣ 🫁 : https://lnkd.in/e7-pm8G2 2️⃣ 🩸: https://lnkd.in/e8AuX6Bq 3️⃣ 🩸: https://lnkd.in/e5zuDFAY 4️⃣ ✅ : https://lnkd.in/eDvtuqTM 5️⃣ 🎙️ : https://lnkd.in/e5xXDkHd
-
🚨 ATTN 🚨: Here is your snapshot of all treatment options that the FDA approved in September 2024 and the clinical implications of these decisions.
OncLive’s September Roundup of Key FDA Approvals in Oncology
onclive.com
-
🔔 Tune in to hear from Giuseppe Curigliano, MD, PhD, as he discusses findings from the phase 3 DESTINY-Breast06 trial of T-DXd in HER2-low or HER2-ultralow metastatic #BreastCancer. 👉 Listen now: https://lnkd.in/eSP3JJ8E
Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast Cancer
onclive.com
-
Isabel Preeshagul discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC. Memorial Sloan Kettering Cancer Center #oncology #NSCLC https://lnkd.in/ecTYd5Wx
Patient-Centered Discussions Will Be Critical to Navigate Treatment Selection in EGFR NSCLC
onclive.com
-
Tune in to WATCH 📹 Jessica Lin, MD, Harvard Medical School - Massachusetts General Hospital, as she discusses key findings from the phase 2 TRUST-I trial in patients with ROS1 fusion–positive non–small cell #LungCancer. ⭐ Watch HERE: https://lnkd.in/er-2yY5v
Dr Lin on the Efficacy and Safety of Taletrectinib in ROS1 Fusion NSCLC
onclive.com
-
Do you manage patients with NF1-PN? Register today for our national broadcast with Drs. Lobbous & Chow. Listen to experts discuss challenges with current management options, the challenges for adult patients with NF1-PN and the transition from pediatric care. bit.ly/3zu9MVX
-
The FDA has approved Cologuard Plus, a next-generation multitarget stool DNA test, for adults at least 45 years of age who are at average risk for CRC. #oncology #CRC https://lnkd.in/ecHZ_rsr
FDA Approves Cologuard Plus for Adults at Average Risk for CRC
onclive.com